IL1B and disease of the tendon: Future therapeutic strategies could focus on targeting this cytokine network, particularly disrupting the chronic inflammatory state maintained by the IL-1β/NF-κB axis, potentially offering new avenues for the fundamental treatment of tendinopathy (Figure 5).